Interestingly, adherence to statins and BP medications were positively correlated with participating in one or more of the optional questionnaires of UK Biobank. (8/n)

None of the pharmacogenes we tested showed an effect on adherence. (6/n)

We then turned to genetics, the first suspect being relevant and well established pharmacogenes. CYP2C9 intermediate met. (higher risk of fluvastatins side effects) associated with lower odds of persistence. Similar for tamoxifen and CYP2D6 poor met. (lower drug response). (5/n)

We first considered the effect 8 health and sociodemographic factors.

Non-Finnish/Swedish mother tongue (proxy for recent immigration) and receiving social assistance benefits (lower socio-economic status) showed the biggest effects on both phenotypes, across all meds. (4/n)

We looked at these phenotypes across 5 relevant med classes, including up to N=1 814 591.

We explored health and socio-demographic factors in the nation-wide Finregistry data, and genetics for the subset of ppl from FinnGen.

We replicated our results in Estonian Biobank. (3/n)